Iaso Bio Launches 30,000-Square-Meter Global R&D Center in Shanghai to Advance Cell and Gene Therapies

May 21, 2025 10:55 CST Updated 10:55

IASO Biotechnology

Cancer Treatment New Drug Developer

On May 20, 2025, IASO Bio's Global Research and Development Center in the Waigaoqiao Bonded Area, Shanghai, was officially launched.

Shanghai Waigaoqiao Bonded Area is known as "The Place Closest to the World"Known as the first batch of pilot areas in China that allow foreign investment in stem cell and gene therapy technology research and development as well as product manufacturing, it provides comprehensive policy support for the cell and gene industry, including bonded R&D, bonded production, customs facilitation, clinical trials, and more."IASO Bio Global R&D Center, with a construction area of approximately 30,000 square meters, will leverage the unique policy advantages of the Waigaoqiao Bonded Area to establish cutting-edge cell and gene therapy technologies.In the future, the center will strengthen the synergistic effect with the headquarters of Nanjing IASO Biotherapeutics Co., Ltd., and radiate to the global market, accelerating the in-depth development of international business.

Mr. Yu Yong

Chairman of Waigaoqiao Group

Today, the soon-to-be-launched global R&D center is not only a strategic fulcrum for IASO Bio to enhance its global competitiveness, but also an important practice for the Free Trade Zone Bonded Area to contribute to Pudong's efforts in building a world-class biopharmaceutical industry cluster.

Professor Qi Lu-gui

Blood Disease Hospital, Chinese Academy of Medical Sciences

Chief Clinical Expert (Institute of Hematology, Chinese Academy of Medical Sciences)

Fokasol^®Has successfully participated in three international multicenter studies, demonstrating the strength and responsibility of Chinese pharmaceutical companies. IASO Bio is driving the development of Fokosu.^®The registration clinical study for second/third-line indications is very courageous. It also demonstrates their confidence, and I myself am very confident that this product will get better and better.

Mr. Zheng Weining

Founder of Shenzhen Canyou Group

Our collaboration with IASO Bio aims to help more disabled individuals and patients overcome physical limitations and restore their ability to work through CGT technology. In the future, we look forward to creating more job opportunities suitable for disabled people together with IASO Bio, achieving a harmonious resonance between industrial development and social integration.

Ms. Zhang Jinhua

Founder, Chairman and Chief Executive Officer of IASO Bio

Thank you to the Pudong New Area, the Bonded Area Administration, and the Waigaoqiao Group for providing IASO Bio with a three-dimensional support system of 'spatial empowerment + capital assistance + service enhancement.' This innovative ecosystem offers strong developmental support for IASO Bio's Global Research and Development Center, which will help us accelerate innovation.

Thank you to clinical experts, partners, investors, and industry colleagues from China and abroad for your presence and support. With the Waigaoqiao Bonded Area as our strategic fulcrum, we will fully promote the development of China's cell therapy field and global cooperation.

IASO Bio will continue to push the boundaries of life science with an indomitable spirit of innovation and strong independent R&D capabilities. Staying true to its original mission, it is committed to bringing the hope of a cure to patients worldwide.

At the launch ceremony, the attending guests jointly lit the button symbolizing innovation and hope, witnessing IASO Bio ushering in a new chapter of global development.

At the event, IASO Bio reached important strategic cooperation with partners from Japan, Mexico, Russia, Indonesia, and other countries, as well as with Shenzhen Canfriend Group. The cooperation will focus on advancing two key directions:On the one hand, accelerate the registration and commercialization of CAR-T products in overseas markets, and on the other hand, introduce advanced international stem cell treatment technologies and products to expand the therapeutic areas and benefit a broader patient population globally.

About IASO Bio

IASO Bio, established in 2017, is a leading biopharmaceutical company focusing on the research, production, and sales of innovative cell therapies. The company uses the development of hematological tumor cell drugs as its innovative foundation and expands into the field of autoimmune diseases and antibody-based drugs, possessing comprehensive capabilities across the entire process from early drug discovery, clinical development, regulatory submission to commercialization. IASO Bio currently has more than 10 innovative drug candidates at various stages of development, including the world's first fully human CAR-T product, an anti-BCMA injectable called Equecabtagene Autoleucel (brand name: Fokesu).^®) was approved for marketing by the China National Medical Products Administration (NMPA) in June 2023 for the treatment of adult patients with relapsed or refractory multiple myeloma (R/RMM) who have progressed after at least three prior lines of therapy (including at least one proteasome inhibitor and one immunomodulatory agent). Its frontline indication for treating 2-3 line multiple myeloma (MM) has entered Phase III clinical trials. Additionally, the injectable Ixazomib has obtained multiple Investigational New Drug (IND) application approvals in both China and the United States for autoimmune diseases.

At the same time, CT120, a dual-target (CD19/CD22) product for lymphoma, is about to enter Phase II clinical trials. Another product targeting GPRC5D for the treatment of relapsed and refractory multiple myeloma, IASO118, has received IND approval in China. In addition to cell therapy products, the company's fully human anti-CD19 antibody product, IASO-782, has obtained IND approval for the treatment of multiple autoimmune diseases in both China and the United States, while still exploring more indications for autoimmune diseases. The company has successively reached global commercial expansion licensing or research and development cooperation agreements with overseas cell therapy companies Sana Therapeutics, Cabaletta Bio, and Umoja Biopharma, actively exploring the development of next-generation cell therapy products. Relying on its strong management team, innovative product pipeline, self-owned GMP manufacturing, and advanced clinical development capabilities, IASO Bio is making every effort to bring transformative, accessible innovative therapies and the hope of a cure to patients in China and around the world.

E.N.D

Previous article recommendation:(Click the article title below to open the original text)

A Cell and Gene Therapy Company Opens in China

Sichuan Issues New Policy, Targeting Cell and Gene Therapy Tracks, Expanding Pilot Medical Institutions for Stem Cell Clinical Research, and Supporting Enterprises in Collaborating with Medical Institutions to Develop Cell and Gene Therapy Products

The World's First Exosome Cell Therapy Approved for Market Launch Soon: How to Breakthrough in Exosome Production Processes?

Nearly 100 Million Yuan! A Chinese Organoid Company Secures B Round Financing

Disease Control Rate Reaches 100%, TsingHui LianNuo's Universal CAR-γδ T Cell Therapy Approved for Clinical Trials

Bionno Bio's Allogeneic Universal CAR-T Therapy Achieves Breakthrough: World's First Deep Remission in Lupus Treatment with Superior Safety

Chinese Academy of Sciences Develops New Technology for Exosome Isolation and Purification, High-Purity Exosomes Obtainable in 3 Minutes

Bend Gene's World's First In Vivo Gene Editing Treatment for Viral Keratitis Drug Initiates Phase II Clinical Trial

Priced over 22 million yuan! A gene therapy drug approved for marketing

Single Dose Administration, 72-Week Stable Efficacy! Regeneus Gene Announces Latest Clinical Research Data of ART001, the World's First Non-Viral Vector In Vivo Gene Editing Drug Approved for Clinical Trials in China and the US

Statement：Content sourced from IASO Bio's official channels, ThisThis article aims at knowledge sharing, all content is for reference only and does not constitute any advice.